Presentation at Antibody Engineering & Therapeutics Europe 2023 by Judicaël Parisot, PhD

The Carterra LSA platform is the leading platform for high-throughput kinetics and epitope analysis (HT-SPR technology) of mAbs and protein therapeutics. The new LSAXT platform has enhanced sensitivity, further extending the application space of HT-SPR to include molecule classes such as kinase inhibitors, PROTAC®S, and transient interactions like Fc Receptors.  Selection of bi and tri-specific binders often requires the screening of large combinatorial sample sets derived from panels of monospecific binders.  The Carterra LSA and LSAXT make analyzing the binding properties of these combinatorial panels straightforward and requires minimal amounts of mAb sample and antigen. The affinity of the binders to the targets can be measured in several assay formats and used to verify the independence and activity of each binding site for hundreds of clones. Along with the binding kinetics and specificity measurements, the LSA and LSAXT enable large scale epitope binning to ensure diverse sets of clones are being carried forward to functional evaluation.

Posted by Judicaël Parisot, PhD